German Ruling Will Prevent Original Products Being Split For Distribution
This article was originally published in The Pink Sheet Daily
Executive Summary
A German court ruling should protect high-cost original product drugs from being split by re-packagers and sold in smaller batches for profit.
You may also be interested in...
European Notebook: Price Freezes, European Elections To Feature In 2014
This month’s European Notebook scans the horizon for European legislative and regulatory changes affecting the pharmaceutical industry in the next 12 months, including drug price freezes in Germany and the U.K., the heated debate over clinical trial data transparency, the start of the EU unitary patent, and more.
EU Tackles Counterfeits, But Parallel Trade Poses Tough Issues
Tackling counterfeit drugs is one pillar of the European Commission's package of new proposed pharmaceutical legislation. It will mean higher costs for most drug firms, while significant loopholes will remain
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.